Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 2

2280 - Prognosis of mastectomy with reconstruction after neoadjuvant chemotherapy: a nationwide study in Korean Breast Cancer Society


29 Sep 2019


Poster Display session 2


Tumour Site

Breast Cancer


Sungmin Park


Annals of Oncology (2019) 30 (suppl_5): v55-v98. 10.1093/annonc/mdz240


S. Park1, S.Y. Bae2

Author affiliations

  • 1 Department Of Breast Surgery, Chungbuk National University Hospital, College of Medicine, Chungbuk National University, 28644 - Cheongju/KR
  • 2 Department Of Surgery, Korea University Anam Hospital, 136 705 - Seoul/KR


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 2280


We compared the prognosis of patients with breast cancer according to surgical options including mastectomy with reconstruction after neoadjuvant chemotherapy (NAC). We also assessed the association between prognosis and surgical options according to clinical stage and clinical response in patients with neoadjuvant chemotherapy.


A total of 140,712 patients were enrolled in the Korean Breast Cancer Society Registry database between 2000 and 2014 in Korea. We compared the prognosis of three groups; 1) patients who underwent breast-conserving surgery (BCS), 2) patients who underwent mastectomy, and 3) patients who underwent mastectomy with reconstruction.


Of all 6,634 patients who were treated with NAC, 1,745 patients underwent BCS, 1,459 patients underwent mastectomy, and 363 patients underwent mastectomy with reconstruction. In survival analysis, five-year survival rate (5YSR) of mastectomy with BR group was not inferior compare to other groups in clinical stage IIA and IIB. 5YSR of mastectomy with BR group was 100% and 90.0% clinical stage IIA and IIB, whereas 5YSR of mastectomy group was 97.2% and 86.2% (clinical stage IIA and IIB; P = 0.033 and 0.023). In clinical stage IIIA and IIIB, there was no significant difference in 5YSR between mastectomy with BR group and other groups. However, women who underwent mastectomy with BR had a worse prognosis compare to BCS or mastectomy group in clinical stage IIIC. In univariate analysis by Cox regression method according to surgical methods, women who underwent mastectomy with BR had a worse prognosis compared to other groups in patients with clinical stage IIIC (HR 5.88; 95% CI 2.17-15.89; P < 0.001). In multivariate analysis, women who underwent mastectomy with reconstruction followed by NAC were associated with a worse prognosis in clinical stage IIIC. (HR 3.41; 95% CI 1.29-8.99; P = 0.013).


In this study, women who underwent mastectomy with reconstruction followed by NAC were associated with a worse prognosis in the clinically advanced stage. This study suggests that reconstruction followed by NAC should be considered for appropriately selected patients.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.